Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter study to compare the efficacy and safety of AZA
with or without ATRA in newly diagnosed unfit AML or Intermediate,High or Very High Risk MDS
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University